---
document_datetime: 2025-12-02 05:47:15
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/irbesartan-hydrochlorothiazide-teva.html
document_name: irbesartan-hydrochlorothiazide-teva.html
version: success
processing_time: 0.1725168
conversion_datetime: 2025-12-24 17:33:11.012091
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Irbesartan/Hydrochlorothiazide Teva

[RSS](/en/individual-human-medicine.xml/65829)

##### Authorised

This medicine is authorised for use in the European Union

irbesartan / hydrochlorothiazide Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Irbesartan/Hydrochlorothiazide Teva](#news-on)
- [More information on Irbesartan/Hydrochlorothiazide Teva](#more-information-on-irbesartanhydrochlorothiazide-teva-531)
- [More information on Irbesartan/Hydrochlorothiazide Teva](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach its recommendations on how to use the medicine.

If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis for the CHMP recommendations, read the scientific discussion (also part of the EPAR).

Expand section

Collapse section

## What is Irbesartan/Hydrochlorothiazide Teva?

Irbesartan/Hydrochlorothiazide Teva is a medicine that contains two active substances, irbesartan and hydrochlorothiazide. It is available as tablets (150 mg or 300 mg irbesartan and 12.5 mg hydrochlorothiazide; and 300 mg irbesartan and 25 mg hydrochlorothiazide).

Irbesartan/Hydrochlorothiazide Teva is a 'generic medicine'. This means that Irbesartan/Hydrochlorothiazide Teva is similar to a 'reference medicine' already authorised in the European Union (EU) called CoAprovel.

## What is Irbesartan/Hydrochlorothiazide Teva used for?

Irbesartan/Hydrochlorothiazide Teva is used in adults who have essential hypertension (high blood pressure) that is not adequately controlled by irbesartan or hydrochlorothiazide alone. 'Essential' means that the hypertension has no obvious cause.

The medicine can only be obtained with a prescription.

## How is Irbesartan/Hydrochlorothiazide Teva used?

Irbesartan/Hydrochlorothiazide Teva is taken by mouth. The dose of Irbesartan/Hydrochlorothiazide Teva to be used depends on the dose of irbesartan or hydrochlorothiazide that the patient was taking before. Doses higher than 300 mg irbesartan and 25 mg hydrochlorothiazide once a day are not recommended. Irbesartan/Hydrochlorothiazide Teva may be added to other treatments for hypertension.

## How does Irbesartan/Hydrochlorothiazide Teva work?

Irbesartan/Hydrochlorothiazide Teva contains two active substances, irbesartan and hydrochlorothiazide.

Irbesartan is an 'angiotensin-II-receptor antagonist', which means that it blocks the action of a hormone in the body called angiotensin II. Angiotensin II is a powerful vasoconstrictor (a substance that narrows blood vessels). By blocking the receptors to which angiotensin II normally attaches, irbesartan stops the hormone having an effect, allowing the blood vessels to widen.

Hydrochlorothiazide is a diuretic, which is another type of treatment for hypertension. It works by increasing urine output, reducing the amount of fluid in the blood and lowering the blood pressure.

The combination of the two active substances has an additive effect, reducing the blood pressure more than either medicine alone. By lowering the blood pressure, the risks associated with high blood pressure, such as having a stroke, are reduced.

## How has Irbesartan/Hydrochlorothiazide Teva been studied?

Because Irbesartan/Hydrochlorothiazide Teva is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, CoAprovel. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.

## What are the benefit and risk of Irbesartan/Hydrochlorothiazide Teva?

Because Irbesartan/Hydrochlorothiazide Teva is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why has Irbesartan/Hydrochlorothiazide Teva been approved?

The Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Irbesartan/Hydrochlorothiazide Teva has been shown to have comparable quality and to be bioequivalent to CoAprovel. Therefore, the CHMP's view was that, as for CoAprovel, the benefit outweighs the identified risk. The Committee recommended that Irbesartan/Hydrochlorothiazide Teva be given marketing authorisation.

## Other information about Irbesartan/Hydrochlorothiazide Teva:

The European Commission granted a marketing authorisation valid throughout the EU for Irbesartan/Hydrochlorothiazide Teva on 26 November 2009.

For more information about treatment with Irbesartan/Hydrochlorothiazide Teva, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Irbesartan / Hydrochlorothiazide Teva : EPAR - Summary for the public

English (EN) (91.61 KB - PDF)

**First published:** 16/12/2009

**Last updated:** 10/11/2015

[View](/en/documents/overview/irbesartan-hydrochlorothiazide-teva-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-695)

български (BG) (124.49 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

10/11/2015

[View](/bg/documents/overview/irbesartan-hydrochlorothiazide-teva-epar-summary-public_bg.pdf)

español (ES) (97.33 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

10/11/2015

[View](/es/documents/overview/irbesartan-hydrochlorothiazide-teva-epar-summary-public_es.pdf)

čeština (CS) (118.28 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

10/11/2015

[View](/cs/documents/overview/irbesartan-hydrochlorothiazide-teva-epar-summary-public_cs.pdf)

dansk (DA) (98.04 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

10/11/2015

[View](/da/documents/overview/irbesartan-hydrochlorothiazide-teva-epar-summary-public_da.pdf)

Deutsch (DE) (99.58 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

10/11/2015

[View](/de/documents/overview/irbesartan-hydrochlorothiazide-teva-epar-summary-public_de.pdf)

eesti keel (ET) (96.49 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

10/11/2015

[View](/et/documents/overview/irbesartan-hydrochlorothiazide-teva-epar-summary-public_et.pdf)

ελληνικά (EL) (125.42 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

10/11/2015

[View](/el/documents/overview/irbesartan-hydrochlorothiazide-teva-epar-summary-public_el.pdf)

français (FR) (99.29 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

10/11/2015

[View](/fr/documents/overview/irbesartan-hydrochlorothiazide-teva-epar-summary-public_fr.pdf)

hrvatski (HR) (103.36 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

10/11/2015

[View](/hr/documents/overview/irbesartan-hydrochlorothiazide-teva-epar-summary-public_hr.pdf)

italiano (IT) (98.2 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

10/11/2015

[View](/it/documents/overview/irbesartan-hydrochlorothiazide-teva-epar-summary-public_it.pdf)

latviešu valoda (LV) (113.99 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

10/11/2015

[View](/lv/documents/overview/irbesartan-hydrochlorothiazide-teva-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (114.7 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

10/11/2015

[View](/lt/documents/overview/irbesartan-hydrochlorothiazide-teva-epar-summary-public_lt.pdf)

magyar (HU) (113.38 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

10/11/2015

[View](/hu/documents/overview/irbesartan-hydrochlorothiazide-teva-epar-summary-public_hu.pdf)

Malti (MT) (117.69 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

10/11/2015

[View](/mt/documents/overview/irbesartan-hydrochlorothiazide-teva-epar-summary-public_mt.pdf)

Nederlands (NL) (98.55 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

10/11/2015

[View](/nl/documents/overview/irbesartan-hydrochlorothiazide-teva-epar-summary-public_nl.pdf)

polski (PL) (118.17 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

10/11/2015

[View](/pl/documents/overview/irbesartan-hydrochlorothiazide-teva-epar-summary-public_pl.pdf)

português (PT) (98.38 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

10/11/2015

[View](/pt/documents/overview/irbesartan-hydrochlorothiazide-teva-epar-summary-public_pt.pdf)

română (RO) (115.09 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

10/11/2015

[View](/ro/documents/overview/irbesartan-hydrochlorothiazide-teva-epar-summary-public_ro.pdf)

slovenčina (SK) (115.69 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

10/11/2015

[View](/sk/documents/overview/irbesartan-hydrochlorothiazide-teva-epar-summary-public_sk.pdf)

slovenščina (SL) (105.79 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

10/11/2015

[View](/sl/documents/overview/irbesartan-hydrochlorothiazide-teva-epar-summary-public_sl.pdf)

Suomi (FI) (98.51 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

10/11/2015

[View](/fi/documents/overview/irbesartan-hydrochlorothiazide-teva-epar-summary-public_fi.pdf)

svenska (SV) (96 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

10/11/2015

[View](/sv/documents/overview/irbesartan-hydrochlorothiazide-teva-epar-summary-public_sv.pdf)

## Product information

Irbesartan / Hydrochlorothiazide Teva : EPAR - Product Information

English (EN) (672.13 KB - PDF)

**First published:** 16/12/2009

**Last updated:** 29/01/2025

[View](/en/documents/product-information/irbesartan-hydrochlorothiazide-teva-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-294)

български (BG) (863.32 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

29/01/2025

[View](/bg/documents/product-information/irbesartan-hydrochlorothiazide-teva-epar-product-information_bg.pdf)

español (ES) (704.41 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

29/01/2025

[View](/es/documents/product-information/irbesartan-hydrochlorothiazide-teva-epar-product-information_es.pdf)

čeština (CS) (767.96 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

29/01/2025

[View](/cs/documents/product-information/irbesartan-hydrochlorothiazide-teva-epar-product-information_cs.pdf)

dansk (DA) (690.46 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

29/01/2025

[View](/da/documents/product-information/irbesartan-hydrochlorothiazide-teva-epar-product-information_da.pdf)

Deutsch (DE) (725.75 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

29/01/2025

[View](/de/documents/product-information/irbesartan-hydrochlorothiazide-teva-epar-product-information_de.pdf)

eesti keel (ET) (679.52 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

29/01/2025

[View](/et/documents/product-information/irbesartan-hydrochlorothiazide-teva-epar-product-information_et.pdf)

ελληνικά (EL) (823.66 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

29/01/2025

[View](/el/documents/product-information/irbesartan-hydrochlorothiazide-teva-epar-product-information_el.pdf)

français (FR) (729.96 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

29/01/2025

[View](/fr/documents/product-information/irbesartan-hydrochlorothiazide-teva-epar-product-information_fr.pdf)

hrvatski (HR) (770.2 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

29/01/2025

[View](/hr/documents/product-information/irbesartan-hydrochlorothiazide-teva-epar-product-information_hr.pdf)

íslenska (IS) (643.2 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

29/01/2025

[View](/is/documents/product-information/irbesartan-hydrochlorothiazide-teva-epar-product-information_is.pdf)

italiano (IT) (694.65 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

29/01/2025

[View](/it/documents/product-information/irbesartan-hydrochlorothiazide-teva-epar-product-information_it.pdf)

latviešu valoda (LV) (803.89 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

29/01/2025

[View](/lv/documents/product-information/irbesartan-hydrochlorothiazide-teva-epar-product-information_lv.pdf)

lietuvių kalba (LT) (848.89 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

29/01/2025

[View](/lt/documents/product-information/irbesartan-hydrochlorothiazide-teva-epar-product-information_lt.pdf)

magyar (HU) (746.75 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

29/01/2025

[View](/hu/documents/product-information/irbesartan-hydrochlorothiazide-teva-epar-product-information_hu.pdf)

Malti (MT) (841.88 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

29/01/2025

[View](/mt/documents/product-information/irbesartan-hydrochlorothiazide-teva-epar-product-information_mt.pdf)

Nederlands (NL) (694.09 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

29/01/2025

[View](/nl/documents/product-information/irbesartan-hydrochlorothiazide-teva-epar-product-information_nl.pdf)

norsk (NO) (681.34 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

29/01/2025

[View](/no/documents/product-information/irbesartan-hydrochlorothiazide-teva-epar-product-information_no.pdf)

polski (PL) (810.14 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

29/01/2025

[View](/pl/documents/product-information/irbesartan-hydrochlorothiazide-teva-epar-product-information_pl.pdf)

português (PT) (651.69 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

29/01/2025

[View](/pt/documents/product-information/irbesartan-hydrochlorothiazide-teva-epar-product-information_pt.pdf)

română (RO) (781.91 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

29/01/2025

[View](/ro/documents/product-information/irbesartan-hydrochlorothiazide-teva-epar-product-information_ro.pdf)

slovenčina (SK) (800.16 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

29/01/2025

[View](/sk/documents/product-information/irbesartan-hydrochlorothiazide-teva-epar-product-information_sk.pdf)

slovenščina (SL) (756.34 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

29/01/2025

[View](/sl/documents/product-information/irbesartan-hydrochlorothiazide-teva-epar-product-information_sl.pdf)

Suomi (FI) (666.99 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

29/01/2025

[View](/fi/documents/product-information/irbesartan-hydrochlorothiazide-teva-epar-product-information_fi.pdf)

svenska (SV) (646.42 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

29/01/2025

[View](/sv/documents/product-information/irbesartan-hydrochlorothiazide-teva-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000246641 28/01/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Irbesartan / Hydrochlorothiazide Teva : EPAR - All Authorised presentations

English (EN) (66.13 KB - PDF)

**First published:** 16/12/2009

**Last updated:** 21/05/2013

[View](/en/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-teva-epar-all-authorised-presentations_en.pdf)

[Other languages (23)](#file-language-dropdown-407)

български (BG) (82.62 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

21/05/2013

[View](/bg/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-teva-epar-all-authorised-presentations_bg.pdf)

español (ES) (45.8 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

21/05/2013

[View](/es/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-teva-epar-all-authorised-presentations_es.pdf)

čeština (CS) (42.64 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

21/05/2013

[View](/cs/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-teva-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (71.63 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

21/05/2013

[View](/da/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-teva-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (14.36 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

21/05/2013

[View](/de/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-teva-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (29.86 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

21/05/2013

[View](/et/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-teva-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (100.98 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

21/05/2013

[View](/el/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-teva-epar-all-authorised-presentations_el.pdf)

français (FR) (21.51 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

21/05/2013

[View](/fr/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-teva-epar-all-authorised-presentations_fr.pdf)

íslenska (IS) (68.33 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

21/05/2013

[View](/is/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-teva-epar-all-authorised-presentations_is.pdf)

italiano (IT) (50.3 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

21/05/2013

[View](/it/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-teva-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (97.73 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

21/05/2013

[View](/lv/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-teva-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (64.67 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

21/05/2013

[View](/lt/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-teva-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (98.91 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

21/05/2013

[View](/hu/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-teva-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (75.25 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

21/05/2013

[View](/mt/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-teva-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (66 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

21/05/2013

[View](/nl/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-teva-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (18.4 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

21/05/2013

[View](/no/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-teva-epar-all-authorised-presentations_no.pdf)

polski (PL) (101.7 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

21/05/2013

[View](/pl/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-teva-epar-all-authorised-presentations_pl.pdf)

português (PT) (38.4 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

21/05/2013

[View](/pt/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-teva-epar-all-authorised-presentations_pt.pdf)

română (RO) (51.09 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

21/05/2013

[View](/ro/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-teva-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (61.41 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

21/05/2013

[View](/sk/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-teva-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (67.52 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

21/05/2013

[View](/sl/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-teva-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (71.12 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

21/05/2013

[View](/fi/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-teva-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (24.14 KB - PDF)

**First published:**

16/12/2009

**Last updated:**

21/05/2013

[View](/sv/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-teva-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Irbesartan/Hydrochlorothiazide Teva Active substance

- irbesartan
- hydrochlorothiazide

International non-proprietary name (INN) or common name

- irbesartan
- hydrochlorothiazide

Therapeutic area (MeSH) Hypertension Anatomical therapeutic chemical (ATC) code C09DA04

### Pharmacotherapeutic group

Agents acting on the renin-angiotensin system

### Therapeutic indication

Treatment of essential hypertension. This fixed-dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone.

## Authorisation details

EMA product number EMEA/H/C/001112

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Teva B.V.

Teva B.V.

Opinion adopted 24/09/2009 Marketing authorisation issued 26/11/2009 Revision 24

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Irbesartan / Hydrochlorothiazide Teva : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (141.92 KB - PDF)

**First published:** 29/01/2025

[View](/en/documents/procedural-steps-after/irbesartan-hydrochlorothiazide-teva-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Irbesartan / Hydrochlorothiazide Teva : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (193.3 KB - PDF)

**First published:** 30/03/2010

**Last updated:** 29/01/2025

[View](/en/documents/procedural-steps-after/irbesartan-hydrochlorothiazide-teva-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Angiotensin-II-receptor antagonists (sartans) : Scientific conclusions - Impact of the Article 5(3) scientific opinion on nitrosamines

Adopted

English (EN) (119.28 KB - PDF)

**First published:** 05/07/2021

[View](/en/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_en.pdf)

[Other languages (22)](#file-language-dropdown-114)

български (BG) (145.18 KB - PDF)

**First published:**

05/07/2021

[View](/bg/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_bg.pdf)

español (ES) (125.85 KB - PDF)

**First published:**

05/07/2021

[View](/es/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_es.pdf)

čeština (CS) (139.02 KB - PDF)

**First published:**

05/07/2021

[View](/cs/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_cs.pdf)

dansk (DA) (126.81 KB - PDF)

**First published:**

05/07/2021

[View](/da/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_da.pdf)

Deutsch (DE) (131.05 KB - PDF)

**First published:**

05/07/2021

[View](/de/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_de.pdf)

eesti keel (ET) (123.85 KB - PDF)

**First published:**

05/07/2021

[View](/et/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_et.pdf)

ελληνικά (EL) (139.5 KB - PDF)

**First published:**

05/07/2021

[View](/el/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_el.pdf)

français (FR) (127.12 KB - PDF)

**First published:**

05/07/2021

[View](/fr/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_fr.pdf)

hrvatski (HR) (142.87 KB - PDF)

**First published:**

05/07/2021

[View](/hr/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_hr.pdf)

italiano (IT) (126.56 KB - PDF)

**First published:**

05/07/2021

[View](/it/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_it.pdf)

latviešu valoda (LV) (147.7 KB - PDF)

**First published:**

05/07/2021

[View](/lv/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_lv.pdf)

lietuvių kalba (LT) (148.34 KB - PDF)

**First published:**

05/07/2021

[View](/lt/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_lt.pdf)

magyar (HU) (137.17 KB - PDF)

**First published:**

05/07/2021

[View](/hu/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_hu.pdf)

Malti (MT) (151.21 KB - PDF)

**First published:**

05/07/2021

[View](/mt/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_mt.pdf)

Nederlands (NL) (127.53 KB - PDF)

**First published:**

05/07/2021

[View](/nl/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_nl.pdf)

polski (PL) (137.7 KB - PDF)

**First published:**

05/07/2021

[View](/pl/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_pl.pdf)

português (PT) (128.87 KB - PDF)

**First published:**

05/07/2021

[View](/pt/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_pt.pdf)

română (RO) (143.59 KB - PDF)

**First published:**

05/07/2021

[View](/ro/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_ro.pdf)

slovenčina (SK) (135.07 KB - PDF)

**First published:**

05/07/2021

[View](/sk/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_sk.pdf)

slovenščina (SL) (149.74 KB - PDF)

**First published:**

05/07/2021

[View](/sl/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_sl.pdf)

Suomi (FI) (125.84 KB - PDF)

**First published:**

05/07/2021

[View](/fi/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_fi.pdf)

svenska (SV) (126.99 KB - PDF)

**First published:**

05/07/2021

[View](/sv/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_sv.pdf)

Angiotensin-II-receptor antagonists (sartans) Article 31 referral - CHMP assessment report - Impact of the Article 5(3) scientific opinion on nitrosamines

Adopted

Reference Number: EMA/47245/2021

English (EN) (362.31 KB - PDF)

**First published:** 02/03/2021

[View](/en/documents/variation-report/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-chmp-assessment-report-impact-article-53-scientific-opinion-nitrosamines_en.pdf)

Irbesartan / Hydrochlorothiazide Teva : EPAR - Scientific conclusions - Annex IV

English (EN) (99.42 KB - PDF)

**First published:** 12/06/2019

[View](/en/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-teva-epar-scientific-conclusions-annex-iv_en.pdf)

[Other languages (22)](#file-language-dropdown-932)

български (BG) (136.15 KB - PDF)

**First published:**

12/06/2019

[View](/bg/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-teva-epar-scientific-conclusions-annex-iv_bg.pdf)

español (ES) (98.31 KB - PDF)

**First published:**

12/06/2019

[View](/es/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-teva-epar-scientific-conclusions-annex-iv_es.pdf)

čeština (CS) (131.08 KB - PDF)

**First published:**

12/06/2019

[View](/cs/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-teva-epar-scientific-conclusions-annex-iv_cs.pdf)

dansk (DA) (96.12 KB - PDF)

**First published:**

12/06/2019

[View](/da/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-teva-epar-scientific-conclusions-annex-iv_da.pdf)

Deutsch (DE) (100.2 KB - PDF)

**First published:**

12/06/2019

[View](/de/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-teva-epar-scientific-conclusions-annex-iv_de.pdf)

eesti keel (ET) (94.4 KB - PDF)

**First published:**

12/06/2019

[View](/et/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-teva-epar-scientific-conclusions-annex-iv_et.pdf)

ελληνικά (EL) (142.79 KB - PDF)

**First published:**

12/06/2019

[View](/el/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-teva-epar-scientific-conclusions-annex-iv_el.pdf)

français (FR) (97.56 KB - PDF)

**First published:**

12/06/2019

[View](/fr/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-teva-epar-scientific-conclusions-annex-iv_fr.pdf)

hrvatski (HR) (125.02 KB - PDF)

**First published:**

12/06/2019

[View](/hr/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-teva-epar-scientific-conclusions-annex-iv_hr.pdf)

italiano (IT) (95.54 KB - PDF)

**First published:**

12/06/2019

[View](/it/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-teva-epar-scientific-conclusions-annex-iv_it.pdf)

latviešu valoda (LV) (130.68 KB - PDF)

**First published:**

12/06/2019

[View](/lv/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-teva-epar-scientific-conclusions-annex-iv_lv.pdf)

lietuvių kalba (LT) (130.84 KB - PDF)

**First published:**

12/06/2019

[View](/lt/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-teva-epar-scientific-conclusions-annex-iv_lt.pdf)

magyar (HU) (119.82 KB - PDF)

**First published:**

12/06/2019

[View](/hu/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-teva-epar-scientific-conclusions-annex-iv_hu.pdf)

Malti (MT) (133.78 KB - PDF)

**First published:**

12/06/2019

[View](/mt/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-teva-epar-scientific-conclusions-annex-iv_mt.pdf)

Nederlands (NL) (99.3 KB - PDF)

**First published:**

12/06/2019

[View](/nl/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-teva-epar-scientific-conclusions-annex-iv_nl.pdf)

polski (PL) (130.65 KB - PDF)

**First published:**

12/06/2019

[View](/pl/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-teva-epar-scientific-conclusions-annex-iv_pl.pdf)

português (PT) (96.47 KB - PDF)

**First published:**

12/06/2019

[View](/pt/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-teva-epar-scientific-conclusions-annex-iv_pt.pdf)

română (RO) (128.25 KB - PDF)

**First published:**

12/06/2019

[View](/ro/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-teva-epar-scientific-conclusions-annex-iv_ro.pdf)

slovenčina (SK) (119.14 KB - PDF)

**First published:**

12/06/2019

[View](/sk/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-teva-epar-scientific-conclusions-annex-iv_sk.pdf)

slovenščina (SL) (124.14 KB - PDF)

**First published:**

12/06/2019

[View](/sl/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-teva-epar-scientific-conclusions-annex-iv_sl.pdf)

Suomi (FI) (97.12 KB - PDF)

**First published:**

12/06/2019

[View](/fi/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-teva-epar-scientific-conclusions-annex-iv_fi.pdf)

svenska (SV) (96.85 KB - PDF)

**First published:**

12/06/2019

[View](/sv/documents/scientific-conclusion/irbesartan-hydrochlorothiazide-teva-epar-scientific-conclusions-annex-iv_sv.pdf)

Angiotensin-II-receptor antagonists (sartans) Article 31 referral - CHMP assessment report

Adopted

Reference Number: EMA/217823/2019

English (EN) (531.32 KB - PDF)

**First published:** 02/05/2019

[View](/en/documents/variation-report/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-chmp-assessment-report_en.pdf)

Irbesartan/Hydrochlorothiazide Teva-H-C-1112-A31-0019 : EPAR - Scientific conclusions, grounds for variation to the terms of the marketing authorisations and detailed explanation of the scientific grounds for the differe...

English (EN) (42.12 KB - PDF)

**First published:** 02/10/2014

**Last updated:** 02/10/2014

[View](/en/documents/scientific-conclusion/irbesartanhydrochlorothiazide-teva-h-c-1112-a31-0019-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differe_en.pdf)

[Other languages (22)](#file-language-dropdown-268)

български (BG) (87.49 KB - PDF)

**First published:**

02/10/2014

**Last updated:**

02/10/2014

[View](/bg/documents/scientific-conclusion/irbesartanhydrochlorothiazide-teva-h-c-1112-a31-0019-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differe_bg.pdf)

español (ES) (50.51 KB - PDF)

**First published:**

02/10/2014

**Last updated:**

02/10/2014

[View](/es/documents/scientific-conclusion/irbesartanhydrochlorothiazide-teva-h-c-1112-a31-0019-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differe_es.pdf)

čeština (CS) (82.81 KB - PDF)

**First published:**

02/10/2014

**Last updated:**

02/10/2014

[View](/cs/documents/scientific-conclusion/irbesartanhydrochlorothiazide-teva-h-c-1112-a31-0019-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differe_cs.pdf)

dansk (DA) (49.01 KB - PDF)

**First published:**

02/10/2014

**Last updated:**

02/10/2014

[View](/da/documents/scientific-conclusion/irbesartanhydrochlorothiazide-teva-h-c-1112-a31-0019-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differe_da.pdf)

Deutsch (DE) (53.54 KB - PDF)

**First published:**

02/10/2014

**Last updated:**

02/10/2014

[View](/de/documents/scientific-conclusion/irbesartanhydrochlorothiazide-teva-h-c-1112-a31-0019-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differe_de.pdf)

eesti keel (ET) (50.6 KB - PDF)

**First published:**

02/10/2014

**Last updated:**

02/10/2014

[View](/et/documents/scientific-conclusion/irbesartanhydrochlorothiazide-teva-h-c-1112-a31-0019-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differe_et.pdf)

ελληνικά (EL) (89.54 KB - PDF)

**First published:**

02/10/2014

**Last updated:**

02/10/2014

[View](/el/documents/scientific-conclusion/irbesartanhydrochlorothiazide-teva-h-c-1112-a31-0019-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differe_el.pdf)

français (FR) (51.91 KB - PDF)

**First published:**

02/10/2014

**Last updated:**

02/10/2014

[View](/fr/documents/scientific-conclusion/irbesartanhydrochlorothiazide-teva-h-c-1112-a31-0019-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differe_fr.pdf)

hrvatski (HR) (80.12 KB - PDF)

**First published:**

02/10/2014

**Last updated:**

02/10/2014

[View](/hr/documents/scientific-conclusion/irbesartanhydrochlorothiazide-teva-h-c-1112-a31-0019-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differe_hr.pdf)

italiano (IT) (51.13 KB - PDF)

**First published:**

02/10/2014

**Last updated:**

02/10/2014

[View](/it/documents/scientific-conclusion/irbesartanhydrochlorothiazide-teva-h-c-1112-a31-0019-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differe_it.pdf)

latviešu valoda (LV) (81.63 KB - PDF)

**First published:**

02/10/2014

**Last updated:**

02/10/2014

[View](/lv/documents/scientific-conclusion/irbesartanhydrochlorothiazide-teva-h-c-1112-a31-0019-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differe_lv.pdf)

lietuvių kalba (LT) (82.54 KB - PDF)

**First published:**

02/10/2014

**Last updated:**

02/10/2014

[View](/lt/documents/scientific-conclusion/irbesartanhydrochlorothiazide-teva-h-c-1112-a31-0019-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differe_lt.pdf)

magyar (HU) (68.7 KB - PDF)

**First published:**

02/10/2014

**Last updated:**

02/10/2014

[View](/hu/documents/scientific-conclusion/irbesartanhydrochlorothiazide-teva-h-c-1112-a31-0019-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differe_hu.pdf)

Malti (MT) (84.23 KB - PDF)

**First published:**

02/10/2014

**Last updated:**

02/10/2014

[View](/mt/documents/scientific-conclusion/irbesartanhydrochlorothiazide-teva-h-c-1112-a31-0019-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differe_mt.pdf)

Nederlands (NL) (49.82 KB - PDF)

**First published:**

02/10/2014

**Last updated:**

02/10/2014

[View](/nl/documents/scientific-conclusion/irbesartanhydrochlorothiazide-teva-h-c-1112-a31-0019-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differe_nl.pdf)

polski (PL) (83.62 KB - PDF)

**First published:**

02/10/2014

**Last updated:**

02/10/2014

[View](/pl/documents/scientific-conclusion/irbesartanhydrochlorothiazide-teva-h-c-1112-a31-0019-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differe_pl.pdf)

português (PT) (49.74 KB - PDF)

**First published:**

02/10/2014

**Last updated:**

02/10/2014

[View](/pt/documents/scientific-conclusion/irbesartanhydrochlorothiazide-teva-h-c-1112-a31-0019-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differe_pt.pdf)

română (RO) (88.19 KB - PDF)

**First published:**

02/10/2014

**Last updated:**

02/10/2014

[View](/ro/documents/scientific-conclusion/irbesartanhydrochlorothiazide-teva-h-c-1112-a31-0019-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differe_ro.pdf)

slovenčina (SK) (81.5 KB - PDF)

**First published:**

02/10/2014

**Last updated:**

02/10/2014

[View](/sk/documents/scientific-conclusion/irbesartanhydrochlorothiazide-teva-h-c-1112-a31-0019-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differe_sk.pdf)

slovenščina (SL) (79.79 KB - PDF)

**First published:**

02/10/2014

**Last updated:**

02/10/2014

[View](/sl/documents/scientific-conclusion/irbesartanhydrochlorothiazide-teva-h-c-1112-a31-0019-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differe_sl.pdf)

Suomi (FI) (49.15 KB - PDF)

**First published:**

02/10/2014

**Last updated:**

02/10/2014

[View](/fi/documents/scientific-conclusion/irbesartanhydrochlorothiazide-teva-h-c-1112-a31-0019-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differe_fi.pdf)

svenska (SV) (50.18 KB - PDF)

**First published:**

02/10/2014

**Last updated:**

02/10/2014

[View](/sv/documents/scientific-conclusion/irbesartanhydrochlorothiazide-teva-h-c-1112-a31-0019-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differe_sv.pdf)

Irbesartan/Hydrochlorothiazide Teva-H-C-1112-A31-0019 : EPAR - Assessment Report - Article 31

Adopted

Reference Number: EMA/PRAC/294920/2014

English (EN) (301.42 KB - PDF)

**First published:** 02/10/2014

**Last updated:** 02/10/2014

[View](/en/documents/variation-report/irbesartanhydrochlorothiazide-teva-h-c-1112-a31-0019-epar-assessment-report-article-31_en.pdf)

## Initial marketing authorisation documents

Irbesartan / Hydrochlorothiazide Teva : EPAR - Public assessment report

English (EN) (315.11 KB - PDF)

**First published:** 16/12/2009

**Last updated:** 16/12/2009

[View](/en/documents/assessment-report/irbesartan-hydrochlorothiazide-teva-epar-public-assessment-report_en.pdf)

Committee for medicinal products for human use, summary of positive opinion for Irbesartan/Hydrochlorothiazide Teva

Reference Number: EMEA/592212/2009

English (EN) (33.17 KB - PDF)

**First published:** 25/09/2009

**Last updated:** 25/09/2009

[View](/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-irbesartanhydrochlorothiazide-teva_en.pdf)

#### News on Irbesartan/Hydrochlorothiazide Teva

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13-16 May 2013](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-13-16-may-2013) 17/05/2013

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13-16 May 2013](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-13-16-may-2013) 17/05/2013

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 October 2011](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-october-2011) 21/10/2011

[European Medicines Agency concludes that benefit-risk balance of angiotensin-II-receptor antagonists remains positive](/en/news/european-medicines-agency-concludes-benefit-risk-balance-angiotensin-ii-receptor-antagonists-remains-positive) 20/10/2011

#### More information on Irbesartan/Hydrochlorothiazide Teva

- [Renin-angiotensin-system (RAS)-acting agents: Article-31 referral](/en/medicines/human/referrals/renin-angiotensin-system-ras-acting-agents)

Questions and answers on the review of angiotensin-II-receptor antagonists and the risk of cancer

Reference Number: EMA/CHMP/834168/2011

English (EN) (511.41 KB - PDF)

**First published:** 20/10/2011

**Last updated:** 11/05/2017

[View](/en/documents/opinion-any-scientific-matter/questions-answers-review-angiotensin-ii-receptor-antagonists-risk-cancer_en.pdf)

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-211)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### More information on Irbesartan/Hydrochlorothiazide Teva

- [Renin-angiotensin-system (RAS)-acting agents - referral](/en/medicines/human/referrals/renin-angiotensin-system-ras-acting-agents)
- [Angiotensin-II-receptor antagonists (sartans) containing a tetrazole group - referral](/en/medicines/human/referrals/angiotensin-ii-receptor-antagonists-sartans-containing-tetrazole-group)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 29/01/2025

## Share this page

[Back to top](#main-content)